Palmitoyl Tripeptide-38
C33H65N5O7S
Research Use Only. Palmitoyl Tripeptide-38 is a research compound intended strictly for laboratory and scientific research purposes. It is not approved for human consumption, therapeutic use, or veterinary use. Information on this page is provided for educational and research reference purposes only.
Overview
Palmitoyl Tripeptide-38 is a synthetic lipopeptide composed of a tripeptide chain — lysine, oxidized methionine (dioxymethionine), and lysine — attached to a palmitic acid fatty tail, which helps improve its ability to penetrate lipid-rich surfaces in laboratory settings. It belongs to the broader category of matrikine-mimicking peptides, meaning it is structurally designed to mimic fragments of extracellular matrix proteins and is studied for its potential interactions with matrix components such as collagen and fibronectin. The palmitoyl modification is a common feature among cosmetic research peptides and is thought to influence how the molecule interacts with biological membranes in research models. Published research involving Palmitoyl Tripeptide-38 has largely appeared in studies examining multi-ingredient topical formulations, where it has been included as one component among several actives being evaluated for effects on skin matrix proteins in vitro and in clinical observation settings. As with all entries on this reference site, Palmitoyl Tripeptide-38 is intended strictly for laboratory and research purposes and is not approved or intended for human use.
Compound Data
| CAS Number |
1101448-24-1 |
| Molecular Formula |
C33H65N5O7S |
| Molecular Weight |
676.00 g/mol |
| IUPAC Name |
(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-4-methylsulfonylbutanoyl]amino]hexanoic acid |
| PubChem CID |
71587932
|
Research & Bioactivity
Palmitoyl Tripeptide-38 is a lipopeptide that researchers have studied primarily in the context of extracellular matrix biology and dermal tissue remodeling. Studies have examined its potential role in influencing the synthesis of structural proteins such as collagen and fibronectin, which are key components of the skin's connective tissue framework. Research has investigated this compound as part of multi-ingredient formulations in both clinical and consumer perception trials, where outcomes related to skin surface characteristics were assessed using instrumental analysis methods such as Primos® optical profilometry. In vitro and ex vivo experimental models have also been referenced in the broader literature surrounding lipopeptides of this class, exploring how such compounds interact with keratinocytes and dermal fibroblasts at the cellular level. Several open-label clinical studies have included Palmitoyl Tripeptide-38 within complex topical formulations evaluated for measurable changes in surface parameters, though researchers note the challenges of isolating the contribution of individual ingredients within such multi-component systems.
Also Known As
- Palmitoyl Tripeptide-38
- Palmitoyl lysyldioxymethionyllysine
- UNII-T7A529FB8O
- T7A529FB8O
- 1101448-24-1
- DTXSID50149155
- PALMITOYL-LYSYL-DIOXYMETHIONYL-LYSINE
- L-LYSINE, N2-(1-OXOHEXADECYL)-L-LYSYL-S,S-DIOXIDO-L-METHIONYL-
- RefChem:169737
- DTXCID3071646
- PALMITOYL TRIPEPTIDE-38 [INCI]
- Palmitoyl Tripeptide 38
- 1447824-23-8
- Palmitoyl Tripeptide-38 (acetate)
- Matrixyl Synthe'6
Published Research
A serum containing vitamins C & E and a matrix-repair tripeptide reduces facial signs of aging as evidenced by Primos® analysis and frequently repeated auto-perception.
Lintner K, Gerstein F, Solish N — 2020
BACKGROUND: Allegations on the benefits of incorporating vitamin C, vitamin E, and combinations thereof in topical skincare formulations are mostly based on in vitro and ex vivo experiments and/or limited protocols of specific stress conditions (pollution, UV exposure, laser irradiation,…). OBJECTIVE: To evaluate the instrumentally measurable effects and quantitative consumer perceptions of a protective and reparative serum on a panel of volunteers under normal nonstressed conditions of use, employing FOITS technology and innovative self-assessment methods. METHOD: In an open-label study women of ≥40 years with visible signs of photoaging applied a serum comprising l-ascorbic acid USP (15% w/v), tocopheryl acetate USP, and 5 ppm palmitoyl tripeptide-38 to the face once daily for 56 days. Skin roughness and isotropy changes were evaluated on days 0, 28, and 56, visual instrumental evaluation of skin-tone parameters was assessed on days 0 and 56. Subjects completed self-assessment questionnaires every third day of the trial period for radiance, homogeneity, and wrinkle appearance. RESULTS: Skin-roughness parameters decreased significantly by 8%-9% (P < .05) and subjects experienced a significant increase in skin isotropy (P < .05). Photographic analysis revealed significant improvements in skin tone, with a 9% decrease in redness and 8% increase in homogeneity (P < .0001 for both), in excellent agreement with subjects' perception of significant improvements of radiance, complexion, and wrinkles. CONCLUSION: The study confirms statistically significant correlation between objectively measured and quantitative subjectively perceived benefits of the bespoke serum containing antioxidants and a matrix-restoring peptide.
Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs.
Sanz MT, Campos C, Milani M, Foyaca M, Lamy A, et al. — 2016
BACKGROUND: Epithelial regeneration in skin is achieved by the constant turnover and differentiation of keratinocytes. Epidermal and dermal stem cells compartments are fundamental for the continuous renewal of the skin. Adult stem cells are the unique source for skin tissue renewal. Plants have stem cells and plant derived stem cell extracts are now used in topical products for their potential anti-ageing and anti-wrinkle effects. A new dermocosmetic product containing apple stem cell extract, urea, creatine and palmitoyl tripeptide-38 (Ureadin Fusion Serum Lift Antiarrugas, ISDIN S.A), has been recently developed to target different aspects involved in skin aging. STUDY AIM: To assess in vitro the effects of this new serum on the metabolic functions of human senescent fibroblasts and in vivo the anti-aging effects by clinical and instrumental evaluation. METHODS: We evaluated the effects of the serum on the mitochondrial ROS (reactive oxygen species) production in human senescent cultured fibroblasts measured at 0.1% and 1% using the Mitoread AntiOx mtROS method. In addition we evaluated the anti-ageing in vivo effect of this new serum applied on the face twice daily for 28 consecutive days and assessed by clinical and instrumental evaluation in 32 women with sensitive skin bearing wrinkles on crow's feet. RESULTS: The tested serum both at 0.1% and 1% induces a significant increase in 02 consumption, cellular ATP level and a reduction in extra-cellular lactate concentration. The product reduces also significantly the mitochondrial ROS production. The clinical study shows a relevant anti-wrinkle effect in 71% of the treated women with visible effects in 68% of the subjects as soon as 7 days of treatment. A significant increase in dermal density and skin elasticity was also observed. CONCLUSION: The use of this novel anti-aging serum demonstrated a significant improvement of aging skin signs with first visible results achieved after one week of use. The product seemed to optimize the metabolic functions in human senescent cultured fibroblast restoring a more efficient cell metabolism therefore contributing to the anti-aging properties of the product.
An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin.
Herndon JH, Jiang L, Kononov T, Fox T — 2015
An open label clinical trial was conducted to determine the effectiveness of a multi-ingredient anti-aging moisturizer designed to improve the appearance of facial skin. Parameters studied included fine lines and wrinkles, clarity/brightness, visual roughness, tactile roughness, evenness of skin tone (redness), evenness of skin tone (hyperpigmentation) and overall appearance. Thirty-seven female subjects, ages 35-60 years completed the study. Effective ingredients incorporated into the facial anti-aging moisturizer include: Astragalus membranaceus root extract, a peptide blend including palmitoyl tripeptide-38, standardized rosemary leaf extract (ursolic acid), tetrahexyldecyl ascorbate (THD ascorbate) and ubiquinone (coenzyme Q10). Subjects were instructed to apply the moisturizer twice daily, once in the morning and once in the evening. Subjects were evaluated at baseline and after 4, 8, and 12 weeks of product usage. Clinical evaluations were conducted at each visit. A self-assessment questionnaire was conducted at week 4, week 8, and week 12. The self-assessment questionnaire included product efficacy inquiries and product aesthetic inquiries. Digital photography was conducted at baseline, week 8, and week 12. After 8 weeks of twice daily use, clinical evaluation results show that the multi-ingredient anti-aging moisturizer produced a statistically significant improvement in the scores of all clinical grading parameters assessed compared to baseline. A greater statistically significant improvement was seen at 12 weeks. At week 12, there was a statistically significant percentage of favorable results versus unfavorable results in all product efficacy and product aesthetic self-assessment questionnaire results. Digital photography supported the clinical grading and self-assessment questionnaire results. Additionally, the multi-ingredient anti-aging moisturizer is judged to be mild and well tolerated. Several tolerability parameters were assessed at all time points with no statistically significant increase in any of the scores compared to baseline.